Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Clinical trial supply company strengthens its presence in the European Union
Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
The facility is spread across 215000 sq. feet and provides super-speciality care
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
Circular revenues already at 16% of sales, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime and reusing refurbished parts and systems
Subscribe To Our Newsletter & Stay Updated